{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-035978","form_type":"8-K","ticker":"SRTS","cik":"0001494891","company_name":"Sensus Healthcare, Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.047146+00:00","generated_at":"2026-06-16T00:57:38.805664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sensus Healthcare Q1 2023 revenue $3.4M; net loss $1.9M; expects H2 profitability","bullets":["Revenue $3.4M vs $10.3M YoY; shipped 10 SRT systems vs 33.","Net loss $1.9M ($0.12 per share) vs net income $16.1M ($0.97 per share) in Q1 2022 (included $12.8M gain).","Gross margin fell to 47.1% from 68.9% due to lower volume and vendor cost increases.","Ended Q1 with $19.3M cash, no debt; expects >60 SRT shipments in 2023 and return to profitability in H2.","Management cites inflation impacting dermatologists' cash flow; higher selling & marketing expense."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-035978","json":"https://secwatch.observer/filing/0001213900-23-035978.json","markdown":"https://secwatch.observer/filing/0001213900-23-035978.md","text":"https://secwatch.observer/filing/0001213900-23-035978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1494891/000121390023035978/0001213900-23-035978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1494891/000121390023035978/ea177605-8k_sensus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:57:38.805664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c940d85b9f93b82de1bb2b2ffc71f850e4329fa","claim":"Sensus Healthcare, Inc. reported the three months ended March 31, 2023 results: revenue $3.4 million, net income Net loss was $1.9 million, or $0.12 per share.","evidence_excerpt":"from the first quarter of 2023 and recent weeks include the following (all comparisons are with the first quarter of 2022, unless otherwise indicated): ● Revenues were $3.4 million, compared with $10.3 million, reflecting lower SRT unit sales ● Shipped 10 systems including three SRT systems to Asia and six domestic SRT systems, compared with 33 ● Net loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1494891/000121390023035978/0001213900-23-035978-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$3.4 million"},{"label":"Net income","value":"Net loss was $1.9 million, or $0.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}